PHARMAMAR HA ACTUALIZADO FASE III LAGOON LURBINECTEDIN Y SE RETRASA SU CONCLUSIÓN HASTA ABRIL 2026.
18 junio 2020
Genentech’s Tecentriq in Combination With Chemotherapy (including Abraxane) Meets Primary Endpoint of Improved Pathological Complete Response, Regardless of PD-L1 Status, as Initial Treatment for People With Early Triple-negative Breast Cancer .
Entrada más reciente
Entrada antigua
Inicio